A Phase I/II Study of AMG 510 in Combination With MVASI in Patients With Advanced, Unresectable or Metastatic KRAS G12C Mutant NSCLC With Asymptomatic Brain Metastasis

NCT05180422 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Lack of enrollment

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG: AMG 510
DRUG: MVASI

Sponsor

Criterium, Inc.

Collaborators

[object Object]